Phase 1/2 Clinical Trial of S227928, an Anti-CD74 Antibody-Drug Conjugate Targeting MCL-1, as a Single Agent and in Combination with Venetoclax in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS)/AML, or Chronic Myelomonocytic Leukemia (CMML)

This study is an early-stage clinical trial looking at a new medicine called S227928. It's designed for people with specific blood cancers – Acute Myeloid Leukaemia (AML), Myelodysplastic Syndromes (MDS) that have turned into AML, or Chronic Myelomonocytic Leukaemia (CMML). These are cancers where the body makes too many abnormal blood cells. The study is specifically for patients whose cancer has either come back after treatment or didn't get better with their previous treatments. The new medicine, S227928, works by targeting specific proteins on cancer cells, aiming to deliver a powerful cancer-killing drug directly to them, much like a 'guided missile'.

Researchers want to see if S227928 is safe and if it can help stop the cancer from growing. They are testing it in two ways: first, on its own, and then alongside an existing cancer drug called venetoclax, which is often known as Venclyxto. Venetoclax works by targeting a different protein in cancer cells, so the hope is that combining these two medicines might be more effective than either one alone.

This trial has two main parts, Phase I and Phase II. In Phase I, the focus is on finding the right dose of S227928 and understanding its side effects. In Phase II, once a safe dose is found, the researchers will look closer at how well the treatment helps patients achieve remission, meaning their cancer shows signs of shrinking or disappearing. Understanding these early-stage trials helps pave the way for potential new treatments for these challenging blood cancers.